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Abstract
BACKGROUND—Although recent reports suggest the incidence of parapneumonic empyema 
increased in several regions of the United States, national trends in disease burden are unknown. 
We examined national trends in the incidence of parapneumonic empyema hospitalizations and 
changes in empyema by associated pathogens.
METHODS—National hospitalization data(1996–2008) were analyzed and rates estimated using 
Census estimates as denominators. Incidence rate ratios (IRR) compared 2008 with 1996 rates. 
Discharge diagnosis codes were used to characterize pathogens associated with empyema 
hospitalizations.
RESULTS—Overall, national parapneumonic empyema-related hospitalization rates increased 
from 3.04 per 100,000 in 1996 to 5.98 per 100,000 in 2008, a 2.0-fold increase (95% CI: 1.8–2.1). 
The increases were observed among children (IRR: 1.9 [95% CI: 1.4–2.7]) and adults aged 18–39, 
40–64 and ≥65 years (IRRs: 1.8 [95% CI: 1.5–2.1], 2.0 [95% CI: 1.6–3.1] and 1.7 [95% CI: 1.5–
2.0], respectively). Overall pneumococcal empyema rates remained relatively stable in all age 
groups, whereas streptococcal (non-pneumococcal) and staphylococcal-related empyema rates 
increased 1.9 and 3.3-fold, respectively, with consistent increases across age groups. The overall 
in-hospital case fatality ratio for parapneumonic empyema-related hospitalizations was 8.0% (95% 
CI: 6.4–9.5) in 1996 and 7.2% (95% CI: 6.3–8.1) in 2008 (p=0.395). Of the empyemas where 
study pathogens were listed (37.6%), Staphylococcal-related empyema had the largest absolute 
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increases across age groups and was associated with longer hospital stay and higher in-hospital 
mortality than other empyemas.
CONCLUSIONS—Although parapneumonic empyema-related hospitalizations remained 
relatively rare, they increased substantially during the study period. A number of pathogens, 
especially staphylococcus, contributed to this increase.
INTRODUCTION
Empyema is a relatively rare but serious infection of the pleural space. Despite the wide 
availability of novel antibiotics and improved diagnostic tools, empyema remains an 
important cause of morbidity and mortality.1 Delays in diagnosis, failure to institute 
appropriate antimicrobial therapy, and inadequate drainage contribute to increased morbidity 
and mortality.1–4 In addition, the in-hospital management of empyema patients is associated 
with substantial costs.5
The pathogens traditionally associated with empyema are Streptococcus pneumoniae, 
Streptococcus pyogenes and Staphylococcus aureus.1 However, anaerobes have also been 
identified in 25–76% of cases, as sole organisms or mixed with other bacteria.1, 6 Recently, 
the Streptococcus anginosus (formerly termed Streptococcus milleri)7 group, has been 
reported as a leading bacterial cause of empyema.1, 3, 8 Approximately 40–60% of 
empyemas are considered to be pneumonia-related (i.e. parapneumonic), whereas thoracic 
procedures and trauma account for most of the remainder.1 Most published descriptions of 
empyema come from reports from large healthcare referral centers.
Previous reports suggested that the incidence of parapneumonic empyema was increasing in 
several regions of the United States (US)6, 9–11 and in other countries.4, 12, 13 More recently, 
studies demonstrated national increases in childhood empyema and parapneumonic 
empyema in young children, with various pathogens contributing to these increases.14, 1516 
However, there have been no comprehensive studies of US trends in parapneumonic 
empyemas including both children and adults. We used national hospitalization data to 
examine the patient characteristics and trends of parapneumonic empyema-related 
hospitalizations in the US.
METHODS
Source of data
National hospitalization data were obtained from the Nationwide Inpatient Sample (NIS), 
which is the largest source of inpatient data publicly available in the US. These databases 
contain information on inpatient stays from States that participate in the Healthcare Cost and 
Utilization Project (HCUP), sponsored by the Agency for Healthcare Research and Quality. 
Information recorded includes clinical and resource-utilization data for 5–8 million 
hospitalizations per year from a sample of approximately 1000 hospitals. These hospitals 
constitute an estimated 20% sample of community hospitals, including nonfederal short-
term, general, and specialty hospitals. Participating hospitals are sampled by stratified 
probability sampling in five strata (ownership/control, bed size, teaching status, urban/rural, 
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and region), with sampling probabilities proportional to the number of community hospitals 
in each stratum.17
NIS collects data on all hospitalizations regardless of payment source, and weighting and 
sampling variables are provided to calculate national estimates. Up to 15 discharge 
diagnoses and procedures are recorded using ICD9-CM codes with first-listed diagnoses 
(principal) regarded as the primary reason for hospitalization.18 NIS data are publicly 
available and have no personal identifiers. This study was considered exempt from review by 
the Institutional Review Boards of Vanderbilt University and the CDC.
Empyema identification
We identified parapneumonic empyema hospitalizations using ICD9-CM coded discharge 
diagnoses.15 We first identified all-cause pneumonia hospitalizations by a principal 
diagnosis of pneumonia, or a principal diagnosis of septicemia, meningitis or empyema and 
a pneumonia code in another diagnosis field.15, 19 Discharge diagnosis and procedure codes, 
including thoracentesis and related procedures (including video-assisted thoracoscopic 
surgery, VATS)5, were then used to characterize parapneumonic empyema hospitalizations. 
About 9% of parapneumonic empyema hospitalizations had a primary diagnosis of sepsis/
septicemia or meningitis.
Statistical analyses
Annual incidence rates of parapneumonic empyema hospitalizations were calculated by 
dividing the weighted number of empyemas by annual US Census population estimates. 
Diagnosis codes indicating specific etiologies for empyema-related pathogens (i.e. specified 
pneumonia, septicemia/bacteremia or specific infections) were used to classify empyemas 
into mutually exclusive groups based on the following hierarchy: 1) pneumococcal, 2) 
streptococcal (non-pneumococcal), 3) staphylococcal, and 4) other/unknown pathogens.
Poisson regression models with terms for age group, year and one age-time term interaction 
were fit for each empyema group to obtain annual incidence rates, incidence rate ratios 
(IRRs) and variance estimates while accounting for the NIS sampling design. The unit of 
analysis was the empyema hospitalization and the offset term for these count-events models 
were the census population estimates for specific years and age groups. Thus, for the 
calculation of incidence rates, the aggregated NIS weighted estimates were divided by their 
respective population estimates. All analyses accounted for the NIS weight (DISCWT), 
stratum (NIS_STRATUM and STRATUM) and cluster (HOSPID) design variables. Changes 
in annual empyema rates were examined and summarized by estimating the IRR of the last 
(2008) to the first (1996) annual rates available. Rates, IRRs and their respective 95% 
confidence intervals were calculated using linear combination of coefficients from the fitted 
Poisson models. In addition, rate differences were calculated and tests for linear trends were 
performed evaluating the effect of calendar year on the estimated rates. Mean length of stay, 
number of discharge diagnoses and number of procedures were compared using T tests that 
accounted for the NIS sampling design. In-hospital case fatality ratios were estimated 
dividing the number of in-hospital deaths by the number of empyema-related 
hospitalizations. Since previous empyema studies have focused on young children aged <5 
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years,14, 15 the analyses for the present study were age-stratified as 0–17, 18–39, 40–64 and 
≥65 years old.
To assess the potential effect of changing coding practices on the observed trends, we 
assessed changes in the mean number of discharge diagnosis, procedures and length of stay 
(in days) for all-cause hospitalizations and for parapneumonic empyema-related 
hospitalizations.
Secondary analyses aimed to exclude hospital-acquired empyema and were restricted to 
those patients with a primary discharge diagnosis of empyema. Statistical analyses used the 
survey packages of SAS 9.2 and Stata 11.0.
RESULTS
Characteristics of parapneumonic empyema-related hospitalizations
From 1996 through 2008, we estimated 157094 parapneumonic empyema-related 
hospitalizations in the US (18200 in 2008). The mean patient age was 48.4 years (95% CI: 
47.4–49.4) and 35.8% were female. Race/ethnicity was not reported in 23.7%, and was 
reported as White, African American, Hispanic and other in 56.1%, 8.8%, 6.9%, and 4.7%, 
respectively (Table 1).
Thoracentesis and related procedures were recorded in 86.2% of all parapneumonic 
empyema hospitalizations, and the proportion with any of these procedures was higher 
among children (84.6%) than among adults aged ≥65 years (81.6%). The mean length of 
stay was 15.2 days and was shorter among children than among adults. The overall in-
hospital case-fatality ratio was 7.2% ranging from 0.4% among children to 16.1% among 
adults aged ≥65 years (Table 1).
Assessment of coding practices
During the study years, the mean length of all-cause hospital stay decreased from 5.0 days in 
1996 to 4.6 days in 2008 (p<0.001). Similarly, the mean length of hospital stay for 
parapneumonic empyema-related hospitalizations declined from 16.5 (95% CI: 15.7–17.2) 
in 1996 to 14.9 (95% CI: 14.4–15.4) in 2008 (p<0.001).
For all-cause hospitalizations, there was an increase in the overall mean number of discharge 
diagnoses recorded from 4.5 in 1996 to 7.3 in 2008 (p<0.001). The mean number of 
discharge diagnoses recorded during parapneumonic empyema-related hospitalizations also 
increased from 7.2 (95% CI: 7.0–7.4) in 1996 to 11.8 (95% CI: 11.4–12.2) in 2008 
(p<0.001).
The mean number of procedures recorded during all-cause hospitalizations increased from 
1.4 to 1.6 (p<0.001) during the study years. Similarly, the mean number of procedures 
performed during parapneumonic empyema hospitalizations increased from 4.0 (95% CI: 
3.8–4.3) in 1996 to 4.5 (95% CI: 4.3–4.7) in 2008 (p=0.002). The five most frequent 
procedures listed as first procedures among parapneumonic empyema hospitalizations 
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during 2008 included: insertion of intercostal cathether, decortication of the lung, 
thoracoscopic decortication of the lung, thoracentesis and mechanical ventilation.
Trends in the incidence of parapneumonic empyema hospitalizations
The mean annual rate of parapneumonic empyema hospitalizations varied with age, with the 
largest burden concentrated in the elderly. Mean rates for children were 2.76 per 100,000 
(95% CI: 2.49–3.07), whereas mean annual rates for adults aged 18–39, 40–64 and ≥65 
years were 1.89 (95% CI: 1.82–1.97), 5.41 (95% CI: 5.28–5.56) and 9.94 (95% CI: 9.68–
10.21), respectively. Overall, national rates of parapneumonic empyema hospitalizations 
increased from 3.04 per 100,000 in 1996 to 5.98 per 100,000 in 2008, a 2.0–fold increase 
(95% CI: 1.8–2.1, test for trend p<0.001). In the age-stratified analysis, the largest relative 
increase was observed among adults aged 40–64 years, with rates increasing from 3.96 per 
100,000 in 1996 to 8.10 per 100,000 in 2008, representing a 2.0-fold increase (95% CI: 1.6–
3.1, test for trend p<0.001) (Figure 1).
Parapneumonic empyema hospitalizations also increased among other age groups. Among 
children, rates increased 1.9-fold (95% CI: 1.4–2.7, test for trend p<0.001). Similarly, rates 
increased 1.8-fold (95% CI: 1.5–2.1, test for trend p<0.001) and 1.7-fold (95% CI: 1.5–2.0, 
test for trend p<0.001) among adults aged 18–39 years and ≥65 years, respectively (Figure 
1).
The overall in-hospital case fatality ratio for parapneumonic empyema hospitalizations was 
8.0% (95% CI: 6.4–9.5) in 1996 and 7.2% (95% CI: 6.3–8.1) in 2008 (p=0.395). The rate of 
fatal parapneumonic empyema hospitalizations increased from 0.24 (95% CI: 0.20–0.30) per 
100,000 in 1996 to 0.43 (95% CI: 0.38–0.49) per 100,000 in 2008, a 1.8-fold increase (95% 
CI: 1.4–2.3, test for trend p<0.001).
Empyema related to specific pathogens
Overall, rates of pneumococcal empyema related hospitalizations were 0.68 and 0.74 per 
100,000 in 1996 and 2008, respectively (rate ratio 1.1 (95% CI: 0.9–1.3, test for trend 
p=0.433). Pneumococcal empyema rates remained stable among children (rate ratio 1.1, 
95% 0.7–1.7, p value for test for trend p=0.093) and adults (rate ratios 1.3, 1.2 and 0.8 for 
adults aged 18–39, 40–64 and ≥65 years, respectively).
Rates of streptococcal (non-pneumococcal) empyema increased by 1.9-fold (95% CI: 1.6–
2.4, test for trend p<0.001) during the study period, whereas rates of staphylococcal 
empyema increased by 3.3-fold (95% CI: 2.7–4.0, test for trend p<0.001) (Figure 2). The 
mean length of hospitalizations was also consistently longer for staphylococcal empyema 
than for empyema associated with other pathogens and across age groups. Although the 
frequency of thoracentesis and related procedures was similar among all etiologic groups of 
empyema, the overall in-hospital case fatality ratio was higher among those with 
staphylococcal empyema compared with other groups (Table 2).
There were 62.4% of parapneumonic empyema hospitalizations listed as having other/
unknown etiology. The proportion of other/unknown etiology empyema increased with age 
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and rates of these empyemas increased 2.1-fold (95% CI: 1.9–2.3, test for trend p<0.001) 
(Figure 2).
In the secondary analysis restricted to patients with empyema listed as the primary discharge 
diagnosis (45% of all parapneumonic empyema), the mean length of stay was 14.0 days 
(95% CI: 13.7–14.2) and the case fatality ratio was 5.8% (95% CI: 5.4–6.2), both lower than 
those observed for all parapneumonic empyemas. In this subgroup, the overall rates of 
empyema hospitalizations increased 1.9-fold (95% CI: 1.6–2.1). The increase in children 
was 1.9-fold, and 1.7, 2.0 and 1.5 among adults aged 18–39, 40–64 and ≥65 years, 
respectively. Consistent with the results from the main analyses, overall rates of 
pneumococcal empyema remained stable (IRR: 0.9 (95% CI: 0.6–1.2)), whereas rates of 
streptococcal (non-pneumococcal), staphylococcal and other empyema increased 1.7, 2.9 
and 2.0-fold, respectively.
COMMENT
We used national hospitalization data collected from a period of thirteen years to assess 
changes in the epidemiology of parapneumonic empyema. Our study revealed a substantial 
increase in the incidence of parapneumonic empyema hospitalizations in the US. 
Parapneumonic empyema hospitalizations were commonly associated with in-hospital 
mortality and required long hospital stays. The largest relative increases were observed 
among young adults; however, the largest absolute increases occurred in older populations. 
Our data suggest that the most serious diseases were related to staphylococcal infections. 
Although parapneumonic empyema remains a relatively rare occurrence among children and 
young adults, empyema was more common and associated with a high in-hospital case 
fatality among the elderly. The observed increasing trend is worrisome and consistent with 
previous reports from large healthcare centers or regions within the US and abroad.4, 6, 9–13
Although most empyemas had other/unknown etiology, many pathogens appear to contribute 
to this increase. Among cases classified in our study pathogen-specific groups, 
staphylococcal related-empyema accounted for most of the increase observed during the 
study years and these patients had the longest lengths of stay and the highest in-hospital case 
fatality, suggesting more severe disease than other empyemas. The observed national 
increases in empyema associated with staphylococcal infections are also consistent with 
previous studies performed in large referral healthcare centers.6, 20
In contrast with the increases observed in other empyema groups, the incidence of 
pneumococcal empyema remained stable during the study period in both children and adults. 
It is possible that stable rates of pneumococcal empyema hospitalizations were related to 
direct and indirect protection derived from infant vaccination with a seven-valent 
pneumococcal conjugate vaccine (PCV7) that started in 2000.21–24 Previous studies have 
documented significant reductions in the incidence of pneumonia hospitalizations after 
PCV7 introduction.15, 19 Some studies reported local and regional increases in the frequency 
of pneumococcal empyemas in children. Those increases started in the 1990s9, 25 and 
continued after 2000.10, 11 Most of those increases were related to serotypes not covered in 
the PCV7 formulation, most notably serotype 1.9, 25 A recent study assessed national rates 
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of pneumonia related empyema in children younger than 5 years and observed a significant 
increase among children aged 2–4 years but not among younger children.15 Another study 
that explored national changes in childhood pneumococcal empyema reported stable rates 
from 1997 through 2006.14 The present study, which was not restricted to young children, 
indicates that overall national rates of childhood pneumococcal empyema remained 
relatively stable during the study period. The recent introduction of a 13-valent 
pneumococcal conjugate vaccine in 2010 in the US could provide protection against 
pneumococcal serotypes 1, 3, 7F and 19A, commonly associated with empyema,26, 27 but 
the assessment of those vaccination effects will require additional studies.
A large number of parapneumonic empyemas were classified as due to other or unknown 
pathogens and large increases were observed in this group. Defining the etiology of 
empyema is difficult and whether these increases in empyema due to other or unknown 
pathogens also indicates true emerging trends, reduced or delayed laboratory testing or 
increased use of antibiotics prior to hospitalization or samples collection, is unclear. 
Furthermore, mixed bacterial infections are found in some parapneumonic empyemas28 but 
detailed microbiological information was not available for the present study.
The actual cause of the observed increase in empyema is unclear. The spread of antibiotic-
resistant bacteria, some of which are major empyema pathogens may be a driver of the 
observed increases. It was previously suggested that the failure to initiate appropriate 
antibiotic treatment could result in an increased incidence of this condition. In particular, we 
observed increases in empyema related to staphylococcal infections, which have shown an 
increasing prevalence of antibiotic resistance during the last years.4 The increasing incidence 
of infections due to antibiotic-resistant pathogens in the US is well documented,29 with S. 
pneumoniae being the major exception as the incidence of invasive pneumococcal disease 
caused by resistant strains has decreased markedly following PCV7 introduction.30
It is also possible that the increasing wide availability of new diagnostic techniques, such as 
CT scans, could have contributed to an increased recognition of empyemas and to the 
observed increases.31 Moreover, other changes in the detection and management of 
empyema developed during this period. For instance, VATS became a common procedure 
and studies suggest that it can reduce the hospital length of stay and improve clinical 
outcomes.5, 32 The precise contribution of these changes in early detection and treatment of 
empyemas to the observed trends is unclear. In our study, the mean number of thoracentesis-
related procedures performed during empyema hospitalizations increased throughout the 
study years. Notably, in spite of the increasing incidence of empyema observed, the mean 
length of hospital stay declined and the case fatality ratio associated with this condition 
remained stable. These findings could also be related to increased detection of less severe 
episodes of empyema or more complete coding of these episodes. It is also possible that 
there were more re-admissions for empyema in recent years. Since NIS data lack personal 
identifiers, we did not assess the contribution of multiple admissions for the same person to 
the incidence rates.
Our result must be interpreted in light of several limitations. First, we used coded discharge 
diagnoses to identify parapneumonic empyema and as a systematic review of clinical cases 
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could not be performed, some misclassification of events cannot be ruled out. Our data used 
de-identified information and chart reviews or validation of the empyema discharge 
diagnosis was not feasible. Nevertheless, the vast majority of empyema hospitalizations had 
related procedures listed, suggesting high specificity of the discharge diagnoses. Second, 
although our data provide an overview of national changes in the incidence of 
parapneumonic empyema hospitalizations, a detailed assessment of the clinical 
characteristics of the patients and their microbiological analyses was not possible. Third, our 
study likely included some empyemas that developed during the course of a hospitalization 
(hospital-acquired), which appear to have different outcomes and etiologies than 
community-acquired empyemas.28 Although our study could not specifically distinguish 
hospital-acquired empyemas, a secondary analysis, that focused on a principal diagnosis of 
empyema (used as a surrogate for main reason for hospitalization and thus, community 
acquired empyema), showed results consistent with our main findings. Fourth, although NIS 
provides a valuable resource for the study of US hospitalizations, this resource does not 
collect data from patients who receive their care exclusively from federal institutions, such 
as the Veterans Affairs healthcare institutions; and, therefore we modestly underestimate the 
real disease burden in adults. Finally, our data sources lacked information for the period 
preceding hospital admission, and it is possible that some patients with empyema were 
admitted to the hospital after a previous pneumonia hospitalization or pneumonia managed 
in the ambulatory settings. In this scenario, some empyema hospitalizations could appear 
unrelated to pneumonia and would be excluded leading to an underestimation of the burden 
of parapneumonic empyema.
The etiology of empyema is difficult to establish and we used available information to assess 
etiologies. Some studies used molecular techniques and suggested that a sizable proportion 
of culture-negative empyema was caused by pneumococci, mainly serotype 1.12, 33–36 
Moreover, although recent studies described the Streptococcus anginosus group as a leading 
bacterial cause of empyema3, 8, 28 our ability to discriminate between streptococcal species 
was limited and we only evaluated streptococcal (non-pneumococcal) empyema as a single 
group. Moreover, for a large proportion of patients, particularly older adults, empyema was 
recorded as other/unknown etiology.
In conclusion, our study demonstrated a substantial increase in the incidence of 
parapneumonic empyema hospitalizations in the US. Compared with other types of 
empyema, staphylococcal-related empyema showed the overall largest relative increase 
during the study period and was associated with relatively longer hospital stays and higher 
mortality.
Acknowledgments
Financial support. This study was funded by the Centers for Disease Control and Prevention through a 
Cooperative Agreement with the Association for Prevention Teaching and Research (TS-1454). Dr. Grijalva is 
supported by a CDC career development award (K01 CI000163).
Appendix
ICD9-CM codes used for identification of parapneumonic empyema hospitalizations
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What is the key question?;
This study examined changes in the incidence of parapneumonic empyema 
hospitalizations and associated pathogens in the United States
What is the bottom line?; and
Parapneumonic empyema-related hospitalizations have increased substantially during the 
last years. A number of pathogens, especially staphylococcus, contributed to this 
increase.
Why read on?
Empyema is a relatively rare yet very serious disease. This article describes recent 
increases in its incidence and highlights the need for preventive strategies.
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Figure 1. Trends in parapneumonic empyema-related hospitalizations, United States 1996–2008
Date are from the Nationwide Inpatient Sample.
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Figure 2. Trends in parapneumonic empyema-related hospitalizations by different pathogens, 
United States 1996–2008
Date are from the Nationwide Inpatient Sample. *Note the scale change for other/unknown 
empyema estimates.
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Table 2
Selected characteristics of parapneumonic empyema-related hospitalizations by associated pathogens, United 
States 1996–2008
Age and empyema group Age, mean (95% CI) Thoracentesis*, % Length of stay, mean (days) In-hospital case-fatality, %
Less than 18 years old
 Pneumococcal 4.6 (4.4–4.9) 89.1 (86.6–91.6) 13.2 (12.6–13.9) 0.6 (0.2–1)
 Streptococcal (non-pneumococcal) 5.3 (4.9–5.7) 90.1 (87.4–92.9) 12.8 (11.9–13.6) 0.8 (0–1.5)
 Staphylococcal 4.2 (3.7–4.7) 86.6 (83.6–89.6) 16.3 (15.1–17.6) 0.7 (0–1.4)
 Other/Unknown 5.5 (5.3–5.7) 81.3 (78.9–83.7) 10.2 (9.8–10.6) 0.2 (0.1–0.4)
18–39 years
 Pneumococcal 31.1 (30.6–31.6) 92.2 (90.1–94.4) 16.8 (15.5–18) 2.5 (1.3–3.8)
 Streptococcal (non-pneumococcal) 30.3 (29.7–31) 95.5 (93.7–97.3) 15.3 (14.2–16.4) 2.3 (1–3.5)
 Staphylococcal 30.6 (30.1–31.2) 90.3 (87.9–92.6) 18 (16.9–19.2) 2.8 (1.4–4.1)
 Other/Unknown 30.8 (30.5–31) 90.5 (89.4–91.7) 13 (12.5–13.4) 2.1 (1.5–2.6)
40–64 years
 Pneumococcal 52 (51.7–52.4) 93.3 (92.1–94.6) 17.8 (17.1–18.5) 6.1 (4.9–7.3)
 Streptococcal (non-pneumococcal) 52.3 (51.9–52.7) 92.9 (91.5–94.2) 16.6 (15.8–17.3) 4.4 (3.4–5.5)
 Staphylococcal 52 (51.7–52.4) 84.6 (82.8–86.5) 21.7 (20.7–22.6) 8.9 (7.4–10.4)
 Other/Unknown 51.8 (51.6–51.9) 87.3 (86.5–88.1) 14 (13.7–14.2) 4.4 (4–4.9)
65 or more years
 Pneumococcal 76.8 (76.3–77.2) 88.6 (86.6–90.6) 17.4 (16.7–18.1) 15.3 (13.2–17.4)
 Streptococcal (non-pneumococcal) 76.5 (76–77) 89.9 (88–91.7) 16.9 (16–17.7) 12.1 (10–14.2)
 Staphylococcal 76.3 (75.9–76.7) 79.4 (77–81.7) 21.4 (20.3–22.5) 21.8 (19.4–24.1)
 Other/Unknown 76.8 (76.6–77) 79.4 (78.3–80.5) 15.7 (15.3–16.1) 15.7 (14.7–16.6)
*
Includes thoracentesis-related procedures (ICD9-CM: 34.04, 34.06, 34.09, 34.21, 34.51, 34.52, 34.91)
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